Genset deal with Wyeth, plans marketing push

18 October 1999

Genset of France has signed a new gene libraries agreement, replacing aprevious deal, with the Genetics Institute unit of Wyeth-Ayerst, which the firms say will provide them with a larger variety of potential products and targets.

Pascal Brandys, Genset's chief executive, also announced the launch of a direct marketing initiative. He said that the firm had "noted growing interest from pharmaceutical and biotech companies to access our expanded gene libraries," and in response to this, further emphasis on marketing should "better address their needs."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight